Journal
JOURNAL OF EXPERIMENTAL MEDICINE
Volume 205, Issue 7, Pages 1687-1700Publisher
ROCKEFELLER UNIV PRESS
DOI: 10.1084/jem.20072016
Keywords
-
Categories
Funding
- Deutsche Forschungsgemeinschaft [SFB633, TR36, TR54]
- European Community [FP6]
- Max-Delbruck-Center for Molecular Medicine
Ask authors/readers for more resources
Cancer is sporadic in nature, characterized by an initial clonal oncogenic event and usually a long latency. When and how it subverts the immune system is unknown. We show, in a model of sporadic immunogenic cancer, that tumor-specific tolerance closely coincides with the first tumor antigen recognition by B cells. During the subsequent latency period until tumors progress, the mice acquire general cytotoxic T lymphocyte (CTL) unresponsiveness, which is associated with high transforming growth factor (TGF) beta 1 levels and expansion of immature myeloid cells (iMCs). In mice with large nonimmunogenic tumors, iMCs expand but TGF-beta 1 serum levels are normal, and unrelated CTL responses are undiminished. We conclude that (a) tolerance to the tumor antigen occurs at the premalignant stage, (b) tumor latency is unlikely caused by CTL control, and (c) a persistent immunogenic tumor antigen causes general CTL unresponsiveness but tumor burden and iMCs per se do not.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available